
|Videos|July 13, 2023
THOR: Erdafitinib vs Chemotherapy in Metastatic Urothelial Cancer with FGFR Alterations
Expert oncologists offer insights on recent data from the THOR trial, which compared erdafitinib with chemotherapy in patients with metastatic bladder cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































